

PATH822 – Experimental Cancer Therapeutics (Fall 2017)
COURSE OUTLINE

CO-ORDINATOR: Dr. Christopher Nicol (Email: nicolc@queensu.ca)

DATE, TIME, LOCATION: Fridays, 9:30AM-12:30PM, Cancer Research Institute (CRI) Room 100/101

TA: Elizabeth Lightbody (Email: 8edl2@queensu.ca)

SCHEDULE

Week	Date (Fri.)	Session Leader(s)	Session Title	Student Presentations
1	Sept. 15	C. Nicol	Overview and Introduction to New Drug Development (<i>no presentations</i>)	None
2	Sept. 22	S. Davey	Molecular basis of oncogenic transformation & signalling pathways	None
3	Sept. 29	C. Nicol	Challenges with Current Cancer Therapeutics	TBD
4	Oct. 6	C. Nicol	Experimental Drug Delivery (nanoparticles)	TBD
5	Oct. 13	N. Renwick	Drug Discovery I - (non-small molecules, ie RNAi, DNA vaccines, gene therapy, viruses, etc)	TBD
6	Oct. 20	C. Nicol	Drug Discovery II - (small molecules)	TBD
7	Oct. 27	M. Rauh	Molecular Evaluation of Tumours	TBD
8	Nov. 3	A. Kerr	Novel Imaging (increasing sensitivity for: preclinical testing; selecting responsive patients; molecular imaging agents for ultrasound, PET, CT, fMRI)	TBD
9	Nov. 10	P. Greer	Preclinical Models for Validating Experimental Targets	TBD
10	Nov. 17	W. Parulekar	Clinical Drug Development	TBD
11	Nov. 24	M. Koti	Molecular Basis of Variability in Tumour Responses	TBD
12	Dec. 1	J. Dancy	Clinical Results of Targeted Therapy	TBD
13	Dec. 8	Multiple TBD	Student Oral Grant Defenses	Schedule TBD

TBD, To be determined.

PATH822 – Experimental Cancer Therapeutics (Fall 2017)
COURSE OUTLINE

CO-ORDINATOR: Dr. Christopher Nicol (Email: nicolc@queensu.ca)

DATE, TIME, LOCATION: Fridays, 9:30AM-12:30PM, Cancer Research Institute (CRI) Room 100/101

TA: Elizabeth Lightbody (Email: 8edl2@queensu.ca)

GENERAL COURSE FORMAT:

Each session will begin with students separated into two teams. An initial review of the major details of assigned reading material provided a week in advance will be overseen by the session leader (rapid assessment test ~ 15min), followed by in class team-based learning using cases/problems in the topic area (max time ~ 1.5 hrs). After a 15 min bio-break, individual student presentations of assigned papers will follow. Each student presentation (20 min max) is followed by a question period (10 min) where the presenting student poses two questions to the class. The class responds and discussion goes on from there. Presenters are expected to lead the class discussion. Session leaders add value, corrections, etc. as appropriate. At the end, the session leader and co-ordinator may provide some additional comments or overall appraisal. Students will also select one session topic from which they will write a novel grant proposal designed to overcome a challenge in the field of cancer therapeutics. The course aims are to: 1) provide information on fundamental as well as state of the art concepts being applied to overcome challenges in the field of cancer therapeutics; and 2) enhance the student's skills to recognize fruitful areas of research, apply learned concepts, and clearly and concisely articulate their ideas.

EVALUATION

Rapid Assessments	10%
Presentations	30%
Grant Abstract	5%
Grant Proposal	25%
Team Participation	10%
Peer Assessment	5%
Oral Defenses	15%

<p style="text-align: center;">GRANT ABSTRACT & PROPOSAL <i>Choose One Topic from the Sessions</i></p> <p>Due Dates:</p> <ul style="list-style-type: none">• Grant Abstract – 6 Oct. 2017• Grant Proposal – 17 Nov 2017 <p>Send to TA: (Email: 8edl2@queensu.ca)</p>
--

PATH822 – Experimental Cancer Therapeutics (Fall 2017)

COURSE OUTLINE

STUDENT RESEARCH GRANT PROPOSAL TOPICS

Students choose a session topic for which they will write a novel 10 page grant proposal (with budget) designed to overcome a challenge in the field of cancer therapeutics. Prior to writing, students will prepare a brief summary outline, and meet with the Session Leader to confirm the subject is appropriate.

Session Leader(s)	Session Title	Student Grant Proposals
C. Nicol	Challenges with Current Cancer Therapeutics	TBD
C. Nicol	Experimental Drug Delivery	TBD
N. Renwick	Drug Discovery-I (non small molecules)	TBD
C. Nicol	Drug Discovery-II (small molecules)	TBD
M. Rauh	Molecular Evaluation of Tumours	TBD
A. Kerr	Novel Imaging	TBD
P. Greer	Preclinical Models	TBD
W. Parulekar	Clinical Drug Development	TBD
M. Koti	Molecular Basis of Variability in Tumour Responses	TBD
J. Dancey	Clinical Results of ImmunoTargeted Therapy	TBD

SESSION LEADER CONTACT INFORMATION

Name	Email	Queen's Ext.
Dancey, Janet	JDancey@ctg.queensu.ca	36430
Davey, Scott K.	scott.davey@queensu.ca	36923
Greer, Peter A.	greerp@queensu.ca	32813
Kerr, Andrew	Andrew.Kerr@krcc.on.ca	(613) 544-2631 ext.4532
Koti, Madhuri	madhuri.koti@queensu.ca	32498
Nicol, Christopher J.	nicolc@queensu.ca	36531
Parulekar, Wendy R.	WParulekar@ctg.queensu.ca	77745
Rauh, Michael	rauhm@queensu.ca	32818
Renwick, Neil	neil.renwick@queensu.ca	36411